Cargando…

Clinical Applications of Cerebrospinal Fluid Circulating Tumor DNA as a Liquid Biopsy for Central Nervous System Tumors

Central nervous system (CNS) malignancies are associated with poor prognosis, as well as exceptional morbidity and mortality, likely as a result of low rates of early diagnosis and limited knowledge of the tumor growth and resistance mechanisms, dissemination, and evolution in the CNS. Monitoring pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Weiwei, Xu, Tingting, Zhu, Hui, Yu, Jinming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6986252/
https://www.ncbi.nlm.nih.gov/pubmed/32158224
http://dx.doi.org/10.2147/OTT.S229562
_version_ 1783491947240882176
author Yan, Weiwei
Xu, Tingting
Zhu, Hui
Yu, Jinming
author_facet Yan, Weiwei
Xu, Tingting
Zhu, Hui
Yu, Jinming
author_sort Yan, Weiwei
collection PubMed
description Central nervous system (CNS) malignancies are associated with poor prognosis, as well as exceptional morbidity and mortality, likely as a result of low rates of early diagnosis and limited knowledge of the tumor growth and resistance mechanisms, dissemination, and evolution in the CNS. Monitoring patients with CNS malignancies for treatment response and tumor recurrence can be challenging because of the difficulty and risks of brain biopsies and the low specificity and sensitivity of the less invasive methodologies that are currently available. Therefore, there is an urgent need to detect and validate reliable and minimally invasive biomarkers for CNS tumors that can be used separately or in combination with current clinical practices. The circulating tumor DNA (ctDNA) of cerebrospinal fluid (CSF) samples can outline the genetic landscape of entire CNS tumors effectively and is a promising, suitable biomarker, though its role in managing CNS malignancies has not been studied extensively. This review summarizes recent studies that explore the diagnostic, prognostic, and predictive roles of CSF-ctDNA as a liquid biopsy with primary and metastatic CNS malignancies.
format Online
Article
Text
id pubmed-6986252
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-69862522020-03-10 Clinical Applications of Cerebrospinal Fluid Circulating Tumor DNA as a Liquid Biopsy for Central Nervous System Tumors Yan, Weiwei Xu, Tingting Zhu, Hui Yu, Jinming Onco Targets Ther Review Central nervous system (CNS) malignancies are associated with poor prognosis, as well as exceptional morbidity and mortality, likely as a result of low rates of early diagnosis and limited knowledge of the tumor growth and resistance mechanisms, dissemination, and evolution in the CNS. Monitoring patients with CNS malignancies for treatment response and tumor recurrence can be challenging because of the difficulty and risks of brain biopsies and the low specificity and sensitivity of the less invasive methodologies that are currently available. Therefore, there is an urgent need to detect and validate reliable and minimally invasive biomarkers for CNS tumors that can be used separately or in combination with current clinical practices. The circulating tumor DNA (ctDNA) of cerebrospinal fluid (CSF) samples can outline the genetic landscape of entire CNS tumors effectively and is a promising, suitable biomarker, though its role in managing CNS malignancies has not been studied extensively. This review summarizes recent studies that explore the diagnostic, prognostic, and predictive roles of CSF-ctDNA as a liquid biopsy with primary and metastatic CNS malignancies. Dove 2020-01-23 /pmc/articles/PMC6986252/ /pubmed/32158224 http://dx.doi.org/10.2147/OTT.S229562 Text en © 2020 Yan et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Yan, Weiwei
Xu, Tingting
Zhu, Hui
Yu, Jinming
Clinical Applications of Cerebrospinal Fluid Circulating Tumor DNA as a Liquid Biopsy for Central Nervous System Tumors
title Clinical Applications of Cerebrospinal Fluid Circulating Tumor DNA as a Liquid Biopsy for Central Nervous System Tumors
title_full Clinical Applications of Cerebrospinal Fluid Circulating Tumor DNA as a Liquid Biopsy for Central Nervous System Tumors
title_fullStr Clinical Applications of Cerebrospinal Fluid Circulating Tumor DNA as a Liquid Biopsy for Central Nervous System Tumors
title_full_unstemmed Clinical Applications of Cerebrospinal Fluid Circulating Tumor DNA as a Liquid Biopsy for Central Nervous System Tumors
title_short Clinical Applications of Cerebrospinal Fluid Circulating Tumor DNA as a Liquid Biopsy for Central Nervous System Tumors
title_sort clinical applications of cerebrospinal fluid circulating tumor dna as a liquid biopsy for central nervous system tumors
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6986252/
https://www.ncbi.nlm.nih.gov/pubmed/32158224
http://dx.doi.org/10.2147/OTT.S229562
work_keys_str_mv AT yanweiwei clinicalapplicationsofcerebrospinalfluidcirculatingtumordnaasaliquidbiopsyforcentralnervoussystemtumors
AT xutingting clinicalapplicationsofcerebrospinalfluidcirculatingtumordnaasaliquidbiopsyforcentralnervoussystemtumors
AT zhuhui clinicalapplicationsofcerebrospinalfluidcirculatingtumordnaasaliquidbiopsyforcentralnervoussystemtumors
AT yujinming clinicalapplicationsofcerebrospinalfluidcirculatingtumordnaasaliquidbiopsyforcentralnervoussystemtumors